Background Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate incorporating
the human epidermal growth factor receptor 2 (HER2)–targeted antitumor properties of …

Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide,
doxorubicin, vincristine, and prednisone), is the first-line standard of care for patients with …

Purpose The aim of this multicenter-study was to evaluate the progression-free survival,
response rate and toxicity of the combination of bendamustine and rituximab (BR) in patients …

Background The antibody–drug conjugate trastuzumab emtansine is indicated for the
treatment of patients with HER2-positive metastatic breast cancer previously treated with …

Background We characterized the incidence of central nervous system (CNS) metastases
after treatment with trastuzumab emtansine (T-DM1) versus capecitabine–lapatinib (XL), and …

Introduction: The majority of patients with CLL will suffer from infections during their disease,
accounting for approximately 60% of deaths in CLL. Patients are predisposed to infection …

Background Fludarabine-based chemoimmunotherapy with rituximab is frequently used in
patients with indolent and mantle-cell lymphomas who relapse after alkylating …

BACKGROUND This report describes the results of an analysis of patient‐reported
outcomes from EMILIA (TDM4370g/BO21977), a randomized phase 3 study of the antibody …

Abstract Abstract 405 Introduction: Promising results have been observed in two phase-II
studies evaluating the combination of Bendamustine plus Rituximab (BR) in patients with …

The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in
combination with bendamustine and rituximab (pola-BR) for patients with refractory or …